anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for strengthening and/or repairing damage to hair by activating endogenous transglutaminase enzyme in the hair. The method comprises contacting the hair with a mild reducing agent under conditions suitable for activating endogenous transglutaminase present in the hair. Suitably, the mild reducing agent comprises a reducing sugar including glucose, galactose, mannose, lactose, ascorbyl-2-glucoside, L-cysteine or glutathione, and may have a redox potential of less than 600mV. The hair care composition may be formulated as a shampoo, conditioner, wax, gel, paste, spray, mousse or foam. The composition may also include a calcium ion-containing compound. Hair care compositions comprising at least 0.1% w/w of a mild reducing agent are also provided.
This was a multicenter, single arm, open-label phase 2 study. 38 subjects were enrolled to receive daratumumab and dexamethasone. Treatment cycles had a duration of 28 days. Subjects received treatment until either disease progression, death, unacceptable toxicity or for a maximum of 30 months. Drug administration and follow-up visits occurred more frequently for early cycles (weekly for the first 8 weeks, every two weeks for weeks 9-24 and then every 4 weeks). Disease evaluations occurred monthly and involved mainly measurements of myeloma proteins. Other assessments included bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected for albumin, and β2- microglobulin and albumin.
BACKGROUND: Congenital diaphragmatic hernia (CDH) is a rare birth defect with substantial mortality. This study aims to generate a population-based overview of CDH care and outcomes in the Netherlands. Moreover, it assesses interhospital variations between the two Dutch CDH expert centres.
METHODS: This study uses data from the Dutch branch of the European Pediatric Surgical Audit, a prospective clinical audit for congenital anomalies. Data of all patients with CDH treated between 2014 and 2021 were included for epidemiological analysis. For comparative analyses, patients presenting after the neonatal period or not treated in the two CDH expert centres were excluded. Identified interhospital variations were assessed using regression analysis.
RESULTS: In the study period, 283 children with CDH were born, resulting in a national prevalence rate of 2.06/10 000 live births. The patient population, treatment and outcomes at 1 year were comparable between the hospitals, except for length of hospital stay. Regression analysis identified the treating hospital as the strongest significant predictor thereof. Other factors associated with longer length of stay include the presence of other malformations, intrathoracic liver position on prenatal ultrasound, extracorporeal membrane oxygenation treatment, patch repair, complicated postoperative course and discharge to home rather than to another care facility.
CONCLUSION: Outcomes of CDH care throughout the Netherlands are comparable. However, the length of stay differed between the two hospitals, also when adjusting for other covariates. Further qualitative analysis to explain this interhospital variation is indicated. Our findings underscore the potential of clinical auditing as a quality measurement tool in rare conditions.
Standard HPV Vaccination (Comparison District) - In the comparison district, routine HPV vaccination services will be provided to girls aged 10-13 years. The vaccine is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.; A school-based vaccination campaign will be conducted in 2024 November to promote and administer the HPV vaccine. Additionally, the vaccine will be available at health facilities starting in the same month. Outreach activities will also be conducted to ensure access to the vaccine for hard-to-reach populations and out-of-school girls. - Unlike the intervention district, there will be no additional training for nor service by healthcare providers on comprehensive sexuality education (CSE) or other sexual and reproductive health (SRH) services, and there will be no dedicated community outreach sessions on SRH topics.
PURPOSE:To obtain the titled preparation having high stability and resistant to oxidation, by dissolving a 1alpha-hydroxyvitamin D in a medium-chain fatty acid triglyceride essentially free from unsaturated acid, and filling the solution in a soft capsule. CONSTITUTION:The objective preparation is produced by dissolving a 1alpha- hydroxyvitamin D (e.g. 1alpha-hydroxyvitamin D3) in a medium-chain fatty acid triglyceride essentially free from unsaturated acid (e.g. tricaprylic acid glyceride), and filling the solution in a soft capsule. Since the 1alpha-hydroxyvitamin D has high physiological activity, it has to be administered at a dose of as low as 0.5mug. Although it is desirable to administer the compound in the form of a soft capsule by dissolving in an oily base to ensure the accurate dose to the patient, however, it is unstable to heat and light and is liable to be oxidized. A soft capsule preparation having high stability and resistant to oxidization can be obtained by using the above oily base as a solvent.
Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
Preparation of a cosmetic treatment formulation for keratinous material, comprises percolation of a fluid at a pressure of >=3 bars through a composition comprising a cosmetic compound in the form of solid or paste in the presence of a cationic hydrotrope i.e. phenyl/pyridine derivative (I), where the electroneutrality of (I) is assured by an anion or a mixture of anions. Preparation of a cosmetic treatment formulation for keratinous material, comprises percolation of a fluid at a pressure of >=3 bars through a composition comprising a cosmetic compound in the form of solid or paste in the presence of a cationic hydrotrope i.e. phenyl/pyridine derivative of formula (I), where the electroneutrality of (I) is assured by an anion or a mixture of anions. X : CH or N+>R6; R61-10C, preferably 1-6C alkyl; R1H, 1-10C, preferably 1-6C alkyl (when X is N+>R6) or -(CH2)nN+>R3R4R5 (when X is CH); R3-R51-10C alkyl; n : 0-12; R21-4C alkyl; and p : 0-1. Independent claims are included for: (1) a cosmetic treatment of keratinous materials comprising preparing the cosmetic treatment formulation and applying the formulation on keratinous materials; and (2) a packaging device of composition comprising a closed housing bounded by at least a wall at least partially permeable to water vapor under a pressure of >=3 bars, where the composition comprises a cosmetic compound and (I). [Image].
INTRODUCTION: Seroma formation after axillary lymph node dissection (ALND) remains a troublesome complication with significant morbidity. Numerous studies have tried to identify techniques to prevent seroma formation. The aim of this systematic review and network meta-analysis is to use available literature to identify the best intervention for prevention of seroma after standalone ALND.
METHODS: A literature search was performed for all comparative articles regarding seroma formation in patients undergoing a standalone ALND or ALND with breast-conserving surgery in the last 25 years. Data regarding seroma formation, clinically significant seroma (CSS), surgical site infections (SSI), and hematomas were collected. The network meta-analysis was performed using a random effects model and the level of inconsistency was evaluated using the Bucher method.
RESULTS: A total of 19 articles with 1962 patients were included. Ten different techniques to prevent seroma formation were described. When combining direct and indirect comparisons, axillary drainage until output is less than 50 ml per 24 h for two consecutive days results in significantly less CSS. The use of energy sealing devices, padding, tissue glue, or patches did not significantly reduce the incidence of CSS. When comparing the different techniques with regard to SSIs, no statistically significant differences were seen.
CONCLUSIONS: To prevent CSS after ALND, axillary drainage is the most valuable and scientifically proven measure. On the basis of the results of this systematic review with network meta-analysis, removing the drain when output is < 50 ml per 24 h for two consecutive days irrespective of duration seems best. Since drainage policies vary widely, an evidence-based guideline is needed.
The treatment consisted of scapular mobilization with arm movement in all directions for 15 min/session for 3 sessions/week for 4 weeks. Scapular mobilization included scapular upward glide and downward glid. Scapular upward glide was performed with shoulder adduction and extension, while scapular downward glide was performed with shoulder abduction and flexion.
The present disclosure relates to systems and methods for assessing the immunorepertoire and wellness of an individual. This disclosure contemplates an individual submitting: (a) identifying information (such as family medical history, age, gender, and other identifying information) to a database on or accessible by a server by connecting a device, such as a smartphone, to a web application; and (b) a blood sample for immune repertoire processing and submission of the resulting data to the database. The data are processed by a server, which accesses a database. The individual may then access a customized report using a web application accessible by a smartphone or other Internet-connected device. The customized report displays the individuals immunorepertoire indexes. Three immunorepertoire indexes disclosed herein include the: (1) clonotype index; (2) essential index; and (3) diversity index. In certain embodiments, the customized report comprises a graphical representation of the individuals immunorepertoire, with the size of a unique clonotype corresponding with the frequency of such clonotype.
Penicillin G is relatively nontoxic, and dosage adjustments are generally required only in cases of severe renal impairment. The recommended dosage regimens are as follows:

Creatinine clearance less than 10 mL/min/1.73 m 2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 8 to 10 hours. 

Uremic patients with a creatinine clearance greater than 10 mL/min/1.73 m 2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 4 to 5 hours. Additional dosage modifications should be made in patients with hepatic disease and renal impairment. 

For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for Group A β-hemolytic streptococcal infections should be maintained for at least 10 days to reduce the risk of rheumatic fever. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Participating Chinese adults aged 18-84 from Primary Care clinics to validate the risk prediction function. Each subject will complete an assessment on the relevant risk factors and have a blood test on OGTT and HbA1c on recruitment and at 12 months.
Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, \& skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
Older patients seen in the ED are at high risk of functional decline and return visits to the ED. Previous studies have shown that a comprehensive assessment by a geriatric specialist at the time of discharge from the ED along with extensive integration with home services and/or referral to community services can decrease functional decline and return visits to the ED as well as increase patient satisfaction, but this intervention is resource intensive requiring a geriatric discharge specialist to be available to the emergency department 24 hours a day/ 7 days a week. It is also known that in other patient populations telephone reminders to make follow up appointments can increase rate of follow up and that comprehension of discharge instructions is the primary barrier to compliance with discharge instructions. It has been shown that telephone follow-up interviews are feasible for geriatric patients discharged from the ED, and that many elderly patients discharged from the ED do not understand their discharge instructions or attend follow-up appointments. However, there are no published studies evaluating whether a follow up telephone call after discharge from the ED can improve patient compliance with the medical treatment plan including obtaining follow - up appointments and obtaining prescribed medications as well as using them appropriately. We seek to determine if we can increase compliance with medications and outpatient follow up with a phone call from a nurse provider 1-3 days after discharge.
Healing of deep cutaneous wounds often results in detrimental sequelae, including painful and debilitating scars. Current therapies for full-thickness injuries that target specific phases of wound healing have moderate success; however, full resolution remains incomplete and negative consequences persist if skin homeostasis is not achieved. Photoactivated molecules can modulate cellular responses by generating reactive oxygen species and may provide a novel therapeutic option to improve wound healing. In the current study, we investigated the effects of Rose bengal (RB) dye in a preclinical model of full-thickness cutaneous injury. Monochromatic green light activates RB to generate ROS in the presence of oxygen, subsequently crosslinking collagen fibrils. In in vitro studies, we show that photoactivated RB is well tolerated by epidermal keratinocytes and dermal fibroblasts and can mitigate fibrotic signalling by downregulating collagen production. In a murine model of full-thickness injury, topically-applied and photoactivated RB closed wounds faster than control and vehicle treatments and showed significantly improved wound healing outcomes, including enhanced early granulation, better collagen organisation and increased vascularity in the presence of protracted tissue ROS. These data support an overall improved cutaneous wound healing profile after RB phototherapy and warrant further investigations into this versatile molecule.
The invention discloses an infant child interest toy cat model. The infant child interest toy cat model comprises a base, a cushion, a cushion cover and a fixing device. The cushion cover is formed through forming of foaming materials. At least one through hole is formed in the cushion cover. The cushion cover is detachably combined with the base through the fixing device. The cushion is arranged in the cushion cover and composed of a high-density non-woven fabric chair cover and filler contained in the chair cover. The filler is composed of a traditional Chinese medicine layer, an anion natural mineral substance particle layer, an activated carbon particle layer and a memory cotton filling layer. According to the infant child interest toy cat model, mosquitoes can be repelled, anions can be released, and a certain restraining and killing function is achieved on multiple bacteria and fungi. Meanwhile, the aroma is fragrant, freshness and spirit invigoration are achieved, and a comfortable and healthy riding environment without the mosquito interference is provided for a bicycle user.
The present invention provides cDNA target sequences aiming at two siRNAs of a hepatitis b virus gene. SEQ ID NO. 1 is the nucleotide sequence of anti-s siRNA1, and SEQ ID NO. 2 is the nucleotide sequence of anti-s siRNA2. After respectively cotransfecting an HepG2 cell with a report plasmid pGFP-S, the two siRNAs can suppress the expression of green fluorescin of the report gene. After transfecting an HepG2.2.15 cell, the two siRNAs can effectively suppress the expression of HBsAg. Thus, the two siRNAs aiming at the HBV(ayw subtype) S gene can suppress the expression of HBsAg and can be used for preparing medicines for treating HBV chronic infection.
PURPOSE: A composition containing Acorus gramineus extract or alpha-asarone compounds isolated from the extract is provided to prevent and treat neurodegenerative diseases. CONSTITUTION: A composition for preventing and treating neurodegenerative diseases contains Acorus gramineus extract or alpha-asarone of chemical formula 1 isolated from the extract as an active ingredient. The extract is a crude extract or non-polar solven soluble extract. The crude extract is prepared using water, C1-C4 low carbon number alcohol, or a mixture thereof. The neurodegenerative diseases are Alzheimer's disease, Parskinson's disease, stroke, or multiple sclerosis. A health functional food for preventing and treating neurodegenerative diseases contains the extract or alpha-asarone as an active ingredient.
PURPOSE:To control viscosity as desired without degrading the emulsion stability of an emulsion type base material by adding a specific range of ethanol to said material. CONSTITUTION:''Lauromacrogol  '' and stearic monoglyceride are used for emulsifiers, and fatty acids, higher alcohols, vegetable oils, etc. are used for fatty components. Propylene glycol, sorbitol, polyhydric alcohols, refined water, etc. are used for water soluble components, and 0-5w/w% ethanol is added to these. In this time, the amt. of the ethanol to be added is changed, whereby the emulsion type base material of an arbitrary viscosity is obtained without degrading the emulsion stability of the base material.
Background: Formula and breastfeeding are known factors associated with infant weight trajectories. Evidence exploring the effect of expressed human milk feeding on infant weight in the community setting has not been well synthesized. Objectives: This systematic review examined (1) weight changes among infants fed expressed human milk and (2) differences in weight change between infants fed expressed human milk and infants fed at the breast or infant formula via bottle. Methods: A comprehensive search of the literature was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The quality of each study was appraised using the Joanna Briggs Critical Appraisal Tools. Results: A total of six studies met the eligibility criteria and included a total of 5,152 infants. The within-subject analysis identified only 31 infants strictly or predominantly fed expressed human milk. The between-subject analysis comparing expressed human milk feeding to the available comparison groups (formula-fed or direct at the breastfed) revealed that higher weight gains were observed in the weight trajectories among infants in the bottle or formula-fed conditions in four of the six included studies. Conclusions: Findings from the few studies included in this review found a difference in the infant weight gain patterns among expressed human milk-fed infants when compared with their respective feeding groups (directly breastfed or formula-fed). Further research is needed to corroborate these findings and elucidate the clinical significance of the differences in weight gain patterns observed across infant feeding groups.
Several adverse cutaneous reactions have been reported in the literature after SARS-CoV-2 vaccination with emerging reports on chronic spontaneous urticaria (CSU). However, there is little literature of chronic urticaria after COVID-19 boosters in a military population and the impact on operational readiness. We present a retrospective case series of CSU following Moderna COVID-19 booster vaccinations at the US Naval Academy (USNA). Demographics, clinical features, and impact on readiness were evaluated. Forty-nine students from the USNA were evaluated for urticaria after their third COVID-19 booster vaccination. Seventeen individuals were diagnosed with CSU. The median age was 20 years and predominantly male; the median time interval between vaccination and the onset of urticaria was 11 days. Out of 13 referred to Allergy, 7 patients had CU index performed and 2 were positive. Four patients received a second booster vaccination subsequently and did not have any exacerbation of symptoms. Symptoms were controlled with antihistamines, and none required immunomodulator or immunosuppressive therapies. All students were able to complete their commissioning, and none were referred for a medical board. In this series, USNA students who developed CSU after the mRNA COVID-19 Moderna booster vaccine did not have limitations from commissioning, duty status, or issues with subsequent COVID-19 vaccinations.
This invention provides a reagent capable of binding to T cells and having specificity for a unique sequence within the variable region of the  beta  chain of the T cell receptor, the presence of increased number of T cells carrying the unique sequence relative to the number of T cells carrying the sequence present in a normal subject being associated with a specific disease. Specific diseases such as human cancers, e.g. lymphomas; autoimmune diseases, e.g. rheumatoid arthritis; Alzheimer's disease; infectious diseases, e.g. those caused by bacteria, yeast or parasite; or allergies, may be diagnosed as follows. A suitable sample containing T cells is obtained from a subject. The sample is contacted under appropriate conditions with such a reagent. If the subject's cells contain the unique sequence, a detectable complex is formed between the reagent and T cells which contain the sequence. By quantitatively determining the number of T cells containing the sequence present in the complex formed and comparing this number with the number of T cells carrying the sequence determined for a normal subject, the disease with which the unique sequence is associated may be diagnosed. Similar reagents and methods may also be used to detect organ transplant rejection.
This longitudinal study aimed to assess the impact of COVID-19 containment measures on perceived health, health protective behavior and risk perception, and investigate whether chronic disease status and urbanicity of the residential area modify these effects. Participants (n = 5420) were followed for up to 14 months (September 2020-October 2021) by monthly questionnaires. Chronic disease status was obtained at baseline. Urbanicity of residential areas was assessed based on postal codes or neighborhoods. Exposure to containment measures was assessed using the Containment and Health Index (CHI). Bayesian multilevel-models were used to assess effect modification of chronic disease status and urbanicity by CHI. CHI was associated with higher odds for worse physical health in people with chronic disease (OR = 1.09, 95% credibility interval (CrI) = 1.01, 1.17), but not in those without (OR = 1.01, Crl = 0.95, 1.06). Similarly, the association of CHI with higher odds for worse mental health in urban dwellers (OR = 1.31, Crl = 1.23, 1.40) was less pronounced in rural residents (OR = 1.20, Crl = 1.13, 1.28). Associations with behavior and risk perception also differed between groups. Our study suggests that individuals with chronic disease and those living in urban areas are differentially affected by government measures put in place to manage the COVID-19 pandemic. This highlights the importance of considering vulnerable subgroups in decision making regarding containment measures.